- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Initial study will enable further collaboration on the predictive capabilities of StemPrintER Phoenix, AZ, January 8, 2026- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a [...] The post AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) appeared first on AccuStem.
Initial study will enable further collaboration on the predictive capabilities of StemPrintER Phoenix, AZ, January 8, 2026- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a [...] The post AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) appeared first on AccuStem.
Phoenix, AZ and London, UK (September 17, 2025)- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are [...] The post AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning appeared first on AccuStem.
Phoenix, AZ and London, UK (September 17, 2025)- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced an expansion of its blood-based testing capabilities in partnership with EmeritusDX, a rapidly growing cancer diagnostics and information company. The two companies are [...] The post AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning appeared first on AccuStem.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Phoenix, AZ and London, UK (September 16, 2025 – AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced that Wendy Blosser, CEO, will present live at the [...] The post AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th appeared first on AccuStem.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Phoenix, AZ and London, UK (September 16, 2025 – AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced that Wendy Blosser, CEO, will present live at the [...] The post AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th appeared first on AccuStem.
London, UK and Phoenix, AZ, June 16, 2025 - AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. [...] The post AccuStem Sciences, Inc. Announces Chairman Purchase of Shares appeared first on AccuStem.
London, UK and Phoenix, AZ, June 16, 2025 - AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. [...] The post AccuStem Sciences, Inc. Announces Chairman Purchase of Shares appeared first on AccuStem.
London, UK and Phoenix, AZ, June 13, 2025 - AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. [...] The post AccuStem Sciences, Inc. Announces Chairman Purchase of Shares appeared first on AccuStem.
London, UK and Phoenix, AZ, June 13, 2025 - AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 8,991 ACUT shares in the open market. [...] The post AccuStem Sciences, Inc. Announces Chairman Purchase of Shares appeared first on AccuStem.